Acrux and its partner Padagis announced the launch of an AB-rated generic version of Emla® Cream in the United States. Emla® (prilocaine 2.5% and lidocaine 2.5%) Cream is indicated as a topical anaesthetic for use on: normal intact skin for local analgesia; and genital mucous membranes for superficial minor surgery and as pre-treatment for infiltration anaesthesia.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.061 AUD | 0.00% | -4.69% | +38.64% |
04-03 | Acrux, TruPharma Launch Dapsone 5% Gel in US | MT |
02-29 | Transcript : Acrux Limited, H1 2024 Earnings Call, Feb 29, 2024 |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+38.64% | 11.72M | |
+22.69% | 43.81B | |
+24.92% | 23.01B | |
+18.00% | 15.27B | |
+8.91% | 13.68B | |
+42.72% | 11.96B | |
-7.21% | 6.98B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+12.22% | 5.59B |
- Stock Market
- Equities
- ACR Stock
- News Acrux Limited
- Acrux and Padagis Announce the Launch of Prilocaine and Lidocaine Cream in the United States